The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02905916
Recruitment Status : Unknown
Verified September 2016 by Jun Zhu, Peking University. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with age between 18 and 70 years.
Breast cancer, lymphoma, bone tumor or Gynecologic tumor patients.
With multi-cycle chemotherapy.
With III/IV degree neutropenia after the last cycle of chemotherapy and plans to use the same regimen in the subsequent cycles.FN risk of the chemotherapy regimens is ≥20%，or 10%≤FN risk＜20% and has high risk factors associated with FN.
KPS score≥ 70.
Expected to survive more than 3 months.
No hematologic system disease and ANC≥1.5×10E9/L, PKT≥80×10E9/L, Hb≥ 75g/L, WBC≥3×10E9/L, and no bleeding tendency.
Written informed consent are acquired. -
With infection or systemic antibiotic therapy 72h before chemotherapy.
With any abnormal hematopoietic function.
Received transplantation within 3 months.
Suffered from other malignant tumor or brain metastases.
TBIL, ALT,AST > 2.5×ULN; if it were caused by liver metastases, TBIL, ALT,AST >5×ULN.
Cr >1.5 ×ULN.
Sensitive to the product or other genetically engineered biological products from Escherichia coli strains.
Mental or nervous system disorders.
Refused to accept contraceptive measures.
Other situations that investigators consider as contra-indication for this study.